102 results about "Immunomodulating Agent" patented technology

The invention discloses an ultralow-viscosity water-in-oil vaccine adjuvant and a preparation method thereof, and the ultralow-viscosity water-in-oil vaccine adjuvant comprises the following components in percentage by weight: 73%-75% of oil for injection, 20%-23% of a compound emulsifier, 2%-7% of a stabilizer, 0.5%-1.5% of a chiral immunomodulator and 1%-2% of a temperature-responsive material, the preparation method comprises the following steps: heating oil for injection as an oil phase; adding the compound emulsifier, the stabilizer, the chiral immunomodulator and the temperature response type material into the oil phase, stirring until the materials are completely dissolved to form a uniform oil phase mixture, slowly adding the water phase into the oil phase mixture, performing high-speed shearing to form primary emulsion, homogenizing the primary emulsion, and performing freeze drying to obtain the chiral immunomodulator. And carrying out emulsion refining by adopting a micro-fluidic technology to obtain the ultralow-viscosity water-in-oil type vaccine adjuvant. The ultra-low viscosity and injection comfort are achieved, precise immunization is achieved for different pathogens, multiple immune pathways are activated at the same time, a wide and lasting protection effect is generated by training an immune mechanism, and the ultra-low viscosity and injection comfort have the intelligent drug release characteristic, excellent stability and broad-spectrum applicability.

The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I)In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.

Compositions and methods of use for modulating APOE mediated signaling are provided. For example, immunomodulatory agents are provided that reduce APOE expression, ligand binding, crosslinking, APOE mediated signaling, or a combination thereof. In another embodiment, immunomodulatory agents are provided that enhance or promote APOE expression, ligand binding, crosslinking, APOE mediated signaling, or a combination thereof. Such agents can be used to modulate an immune response in a subject in need thereof, wherein the subject has a neurodegenerative disease, such as Alzheimer's disease or cerebral amyloid angiopathy.

The application discloses an active oxygen response type bacteriostatic and repair promoting hydrogel and a preparation method and application thereof, the hydrogel is formed by disulfide bond cross-linked hydrogel in response to active oxygen free radicals in the vagina of vaginitis patients through thiol modified hyaluronic acid (HASH), and can enhance in-vivo retention by thiol and vaginal tissue interaction. Cationic surfactant such as didecyldimethylammonium chloride (DDAC) as the bacteriostatic component of the hydrogel, efficiently killing pathogenic bacteria while having good biocompatibility, and is not prone to cause bacterial drug resistance. As a natural immune regulator, beta-glucan regulates the vaginal microenvironment, promotes the polarization of macrophages into anti-inflammatory M2 type and promotes cell migration, etc., to promote the repair of the vaginal immune barrier, regulate the vaginal flora, and reduce the probability of vaginitis recurrence. The HASH hydrogel provides an efficient, convenient and highly transformative potential strategy to provide more choices for the treatment of vaginitis.

The present invention relates to a PROTAC compound which can increase the degradation effect of a protein of interest, and to a novel piperidinedione compound which can be used as an E3 enzyme ligand of the PROTAC compound. The piperazinedione derivative compound of the present invention acts on CRBN and thus may be used as a therapeutic agent (for example, an anticancer agent or an immunomodulator) for diseases associated with CRBN proteins.

The present invention refers to the field of peptides, particularly with antimicrobial agent activity. Particularly, the present invention refers to peptides comprising the amino acid sequences as defined in the document, useful for treating and / or preventing an infection, preferably for treating and / or preventing animal mastitis, and / or as a preservative and / or as an immunomodulator. The present invention also refers to a set of peptides, to a composition, to uses of at least one peptide or the set of peptides, to a method for treating and / or preventing an infection and a kit.

Embodiments of the invention relate to embolic compositions having immunomodulating components therein and methods for using the embolic compositions to treat cancer. The embolic compositions include a hydrogel embolic with the immunomodulator(s) therein.

This invention relates to the field of plant extract application technology, particularly to banana fruit extract and its applications. This invention reveals that banana fruit extract exhibits excellent performance in relieving inflammation, anti-oxidation, scavenging free radicals, delaying cell aging, inhibiting viruses and bacteria (inactivating HPV, Staphylococcus aureus, Candida albicans, Escherichia coli, and Propionibacterium acnes), reducing infection, promoting cell regeneration and repair, promoting collagen synthesis, enhancing elasticity and firmness, and acting as a plant-derived immunomodulator. Furthermore, it serves as a natural, intelligent transdermal carrier. Safe and non-irritating, this extraction method has shown excellent application value in high-value plants such as saffron, rose, Dendrobium officinale, ginseng, and Ganoderma lucidum. It provides a comprehensive solution for skin from defense to regeneration, offering a regulatory-compliant natural solution for functional skincare.

The invention discloses a biphenyl compound as shown in a formula (I), and a preparation method and application thereof. The invention also relates to a pharmaceutical composition containing the compound as an active ingredient. The compound is a novel small molecule immunomodulator having an excellent oral absorbable characteristic, and can be used for treating and / or preventing various diseases related to immunity.

This invention discloses a preparation process for a homogeneous immunomodulatory polysaccharide from *Gynostemma pentaphyllum* and its application in the preparation of anti-melanoma drugs and immunomodulators, relating to the field of pharmaceutical manufacturing technology. The preparation process includes four steps: compound enzyme-ultrasound synergistic extraction, fractional alcohol precipitation to remove proteins, DEAE-52 ion exchange column chromatography, and Sephacryl S-400 gel permeation chromatography purification. The resulting homogeneous polysaccharide (GOP-3) has a weight-average molecular weight of 12±1 kDa and is composed of mannose, glucose, and galactose in a specific ratio. The GOP-3 of this invention has a weight-average molecular weight (Mw) of 12.8 kDa, a dispersion (Mw / Mn) < 1.2, a uronic acid content of 23.5%, a well-defined structure, and is suitable for drug application. Furthermore, GOP-3 can significantly promote the secretion of IL-12 by dendritic cells and induce the differentiation of naive T cells into Th1 cells. Simultaneously, compared with a full-dose PD-1 monoclonal antibody, the combination of GOP-3 and a half-dose monoclonal antibody not only reduces the risk of immune-mediated pneumonia caused by antibody drugs but also increases the tumor inhibition rate by more than 40%.

This invention discloses a type of click-type covalent drug, its regionally selective delivery system, and its applications. The invention comprises two parts: a click-type covalent drug and a tumor regionally selective delivery system. The click-type covalent drug consists of three parts: an azacyclic alkyne (DBCO), a small molecule drug, and a linker, having the structure of Formula 1. Optionally, the small molecule drug is a membrane protein inhibitor, an immunomodulator, or a chemotherapeutic drug. The click-type covalent drug reacts with azide-labeled target cells via a click reaction, forming a covalent bond that binds to the cell membrane, increasing the local drug concentration and prolonging the drug retention time, thereby enhancing selective inhibition of the target cells. The regionally selective delivery system is co-assembled from an amphiphilic block polymer and the click-type covalent drug for regionally selective delivery. This invention achieves covalent binding to azide-labeled tumor cells through the click-type covalent drug, while having no effect on unlabeled normal cells, reducing toxic side effects on normal tissues.

The application discloses an immunomodulator, and particularly relates to a kind of compounds for inhibiting IL-17A and purposes of the compounds as immunomodulator in preparing medicine.The application discloses purposes of the compound shown in formula I or formula II, or stereoisomer thereof in preparing IL-17A inhibiting medicine, and provides a new choice for screening and / or preparing medicine for the disease related to IL-17A activity in clinic. Formula I Formula II

The invention discloses a biphenyl compound as shown in a formula (I), and a preparation method and application thereof. The invention also relates to a pharmaceutical composition containing the compound as an active ingredient. The compound is a novel small molecule immunomodulator having an excellent oral absorbable characteristic, and can be used for treating and / or preventing various diseases related to immunity.

This disclosure relates to extracellular vesicles (EVs), such as exosomes, comprising a payload (e.g., an antigen, adjuvant, and / or immunomodulator) and / or a targeting portion. Methods for generating EVs (e.g., exosomes) and methods for using EVs (e.g., exosomes) to treat and / or prevent diseases or conditions, such as cancer, graft-versus-host disease (GvHD), autoimmune diseases, infectious diseases, or fibrotic diseases, are also provided herein.

The application discloses a polymer microneedle patch co-loaded with self-antigen peptides and immunomodulators and a preparation method thereof, and studies the ability of the polymer microneedle patch to reverse immune dysfunction of rheumatoid arthritis (RA). The preparation method is as follows: a biocompatible polymer matrix material and a self-antigen are dissolved in pure water, and then an immunomodulator is added to obtain a suspension by stirring. The suspension is added to a mold to form needle tips, a backing layer solution is poured after drying, and finally the microneedle patch is demolded. Animal experiments show that the microneedle has sufficient mechanical strength to deliver drugs transdermally, effectively induces tolerogenic dendritic cells at the drug delivery site, further activates the differentiation of regulatory T cells (Treg), significantly up-regulates anti-inflammatory cytokines, down-regulates pro-inflammatory cells, antibodies and cytokines, effectively restores the immune balance of rheumatoid arthritis, and finally almost completely eliminates the symptoms and inflammatory infiltrates of rheumatoid arthritis. The microneedle preparation method is simple and rapid, and has a good clinical transformation prospect.

The invention discloses a space-time responsive multifunctional 3D printing bone repair scaffold as well as a preparation method and application thereof. PDGF-BB is loaded on a quick-release carrier, MgP is loaded on a slow-release carrier, and the multifunctional 3D printing bone repair scaffold with MgP loaded on the inner layer and PDGF-BB loaded on the outer layer is prepared through 3D printing. Wherein the PDGF-BB is used as an immunomodulator, the MgP is used as a regeneration inducer, and after the carrier is implanted into a body, according to different carrier degradation rates, the PDGF-BB is degraded and released in a space-time responsive manner to realize early immunoregulation and endothelial cell recruitment, and then magnesium ions and phosphate ions are degraded and released to synergistically promote vascularization and osteogenesis in middle and later periods with the PDGF-BB. In-vitro and in-vivo experiments prove that the 3D printing bone repair scaffold provided by the invention has immunoregulation, angiogenesis promotion and osteogenesis properties, can be used for repairing inflammatory bone injury, and is particularly suitable for repairing inflammatory bone injury caused by diabetes.

The present disclosure provides nucleic acids that utilize an intercalated self-cleavable peptide linker (e.g., 2A peptide) to control the expression and / or secretion level of a polypeptide of interest, such as an immunomodulator (e.g., a cytokine, such as IL-2, IL-15, IL-18, or IL-10), also provided are genetically engineered cells (e.g., T cells) carrying such nucleic acids and therapeutic uses of the genetically engineered cells.

This application relates to the field of biomedical technology, and more specifically to the compound represented by formula (I), its pharmaceutically acceptable salt, its deuterated compound, its stereoisomer, its tautomer, or mixtures thereof, and the use of said compound as an immunomodulator for dual targeting of IKZF1 and IKZF3. TIFF2026511128000306.tif30170

The present disclosure also relates to a pharmaceutical composition that comprises the compound as an active ingredient.

The application discloses application of elvitegravir in preparation of an inhibitor of mycobacterium tuberculosis or non-tuberculous mycobacteria, and relates to the technical field of biological medicine.The application discloses, for the first time, that elvitegravir has the effect of inhibiting intracellular survival of mycobacterium tuberculosis or non-tuberculous mycobacteria at the level of macrophages, has the effect of anti-tuberculosis at the level of macrophages, and can be applied to preparation of an inhibitor of mycobacterium tuberculosis or non-tuberculous mycobacteria.The application also discloses that the anti-tuberculosis effect of elvitegravir at the level of macrophages is not the direct action of antibiotics on bacteria, but the inhibition of intracellular survival of tubercle bacillus by targeting and regulating host immune response, so that elvitegravir also has the potential of an immunomodulator, can realize the anti-tuberculosis effect by regulating the immune response of the body to tubercle bacillus infection, and is not affected by drug resistance of mycobacterium tuberculosis, and has a good treatment effect on multidrug-resistant tuberculosis.

The invention relates to application of beta-ionone in preparation of a tumor immunomodulator, and belongs to the technical field of biological medicines. In order to solve the problems of PD-L1 mediated immune escape and insufficient T cell killing activity in existing gastric cancer immunotherapy, the invention provides application of beta-ionone in preparation of a tumor immunomodulator, the tumor immunomodulator is a tumor immune checkpoint inhibitor, and a tumor immune checkpoint is PD-L1; and the tumor immunomodulator is a tumor immunosensitizer. The invention discovers and verifies that beta-ionone has dual immune regulation and control capabilities of immune checkpoint inhibition and immunotherapy sensitization for the first time, and the beta-ionone as an immune checkpoint inhibitor can significantly down-regulate the expression of PD-L1 and weaken immune escape; as an immunotherapy sensitizer, the compound can effectively activate T cells and optimize a tumor immune microenvironment, can significantly enhance the killing effect of the T cells on gastric cancer cells in in-vivo and in-vitro experiments, and has wide clinical application prospects and conversion values.

The invention discloses application of AvBD-5 protein in resisting avian influenza virus infection, and belongs to the technical field of biology. A recombinant plasmid containing a coding sequence of the AvBD-5 protein is transformed into an escherichia coli expression system, IPTG is used for inducing expression of the AvBD-5 protein, the expressed AvBD-5 protein is purified, the high-concentration purified AvBD-5 protein is obtained through ultrafiltration and concentration, the protein can remarkably reduce the virus load of the H9N2 avian influenza virus in in-vivo and in-vitro experiments, and the virus load of the H9N2 avian influenza virus can be remarkably reduced. Meanwhile, the polypeptide has a prominent immunoregulation function, and can specifically inhibit the expression of TLR4 and block the activation of a TLR4 / NF-kappa B signal channel by regulating the immunologic function of red blood cells. The protein can be used as a novel immunomodulator or a drug candidate, and is used for preventing and treating H9N2 avian influenza virus infection.

The application discloses an application of ergothioneine in antiviral in the field of biotechnology. The ergothioneine plays an immune activation role at least by activating TLR4 and downstream NF-kappa B signal pathways. The ergothioneine is used for preparing an immunomodulator or an antiviral drug, can effectively activate immune cells and enhance antiviral capacity, to a certain extent, overcomes defects of traditional technologies, reduces problems of large side effects of current TLR4 agonists, and provides a new idea for developing a novel immunomodulator and an antiviral treatment strategy.

The application belongs to the field of tea polysaccharide research, and discloses a Zijuan tea polysaccharide ZTPW with immunoregulatory activity, and a preparation method and application thereof. The ZTPW is a uniform polysaccharide obtained by hot water extraction and alcohol precipitation of Zijuan tea leaves, and separation and purification through an ion exchange column and a gel column, the main repeating unit structure of which is shown in the following, and the weight average molecular weight thereof is 7.73 kDa. Through in vitro immunoregulatory activity research, the ZTPW can be recognized by pattern recognition receptors TLR2 and TLR4 to activate macrophages, significantly enhance the activity of mouse monocyte macrophage RAW264.7 cells, and mediate the production of NO and cytokines of mouse monocyte macrophage RAW264.7 through MAPKs and NF-kappa B signal pathway, so as to play an immunoregulatory role. The polysaccharide can be used as a potential immunoregulator for the development of functional food or medicine.

This invention discloses an immunomodulator, specifically relating to a class of compounds that inhibit IL-17A and their use as immunomodulators in the preparation of drugs. This invention discloses the use of compounds represented by formula (I), or their stereoisomers, in the preparation of drugs that inhibit IL-17A, providing a new option for clinical screening and / or preparation of drugs for diseases related to IL-17A activity.

The present disclosure provides oncolytic viruses expressing a modulator of interferon regulatory factors (IRFs), and compositions comprising thereof. The present disclosure further provides methods of using said oncolytic viruses and compositions for treating cancer, and for improving a subject's responsiveness to an immunomodulatory agent (e.g., an immune checkpoint inhibitor).

The application provides an absorbable anal fistula repair assembly and a preparation method and application thereof, and comprises a first sheet layer, a second sheet layer and preferably a third sheet layer which are independently formed into a sheet and are prepared from degradable materials; the third sheet layer carries antibiotics, has a complete degradation time of 2-4 weeks, the second sheet layer carries an immunomodulator, has a complete degradation time of 4-12 weeks, and the first sheet layer carries a regeneration and repair regulator, has a complete degradation time of 12-26 weeks, so that the anal fistula repair assembly is degraded in stages and layers, and drugs or preparations are released layer by layer. Experimental results show that the mechanical properties, anti-inflammatory effect and cell proliferation promoting effect of the absorbable anal fistula repair assembly are better, the defects of long drug treatment period and slow treatment effect are overcome, and the very cumbersome operation steps of daily cleaning, dressing change, debridement and disinfection after surgical treatment are avoided, so that the life quality and physical and mental health of patients are improved.

The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (I). The present invention also relates to the use of the compounds of formula (I) to inhibit the programmed cell death 1 (PD1) signaling pathway and / or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

The invention relates to the technical field of medicine, in particular to an IKZF1 and IKZF3 double-target immunomodulator and a preparation method and application of the IKZF1 and IKZF3 double-target immunomodulator serving as antibody coupling medicine toxin. In particular, the invention relates to a ligand drug conjugate or a pharmaceutically acceptable salt or solvate thereof, and a preparation method and application thereof. The invention also relates to a linker drug conjugate or an isomer, a mesomer, a raceme, an enantiomer or a mixture form thereof, or a pharmaceutically acceptable salt or solvate thereof, and a preparation method and application thereof.